Traitement symptomatique de l'occlusion intestinale sur carcinose péritonéale : Recommandations de bonnes pratiques cliniques

Laval, G.; Marcelin-Benazech, Blandine; Arvieux, C.; Chauvenet, L.; Copel, Laure; Durand, Aurélie; François, Ετιεννε; Gabolde, Martine; Guirimand, Frédéric; Mariani, Pascale; Rebischung, Christine; Servois, Vincent; Terrebonne, Éric

doi:10.1016/s1636-6522(12)70003-x

Cited by 5 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of the treatment of symptomatic intestinal obstruction on non-resectable peritoneal carcinomatosis, scientific and medical societies recommend using haloperidol as first-line antiemetic treatment [39]. Oral intake in this context can be a source of discomfort for the patient, and the absorption of the drug is uncertain.…”

Section: Galenic Formsmentioning

confidence: 99%

The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature

Saudemont¹,

Prod’homme

Silva

et al. 2020

BMC Palliat Care

View full text Add to dashboard Cite

Background Olanzapine is an atypical antipsychotic that has affinity for many central nervous system receptors. Its efficacy is supported by several studies in the prevention and treatment of chemotherapy-induced nausea and vomiting. No recommendations exist on the antiemetic use of olanzapine in the palliative care setting. The aim of this work is to complete the initial work of Fonte et al. published in 2015, to determine whether the literature supports the use of olanzapine as an antiemetic in palliative situations and, in practice, to propose a therapeutic schema adapted to the palliative setting. Methods Systematic review of the literature according to the PRISMA criteria. We searched the PubMed, Cochrane, RefDoc, EMBase databases and the gray literature databases. The bibliographic search was conducted between November 2016 and August 2017. Results Thirteen articles were included: 2 case studies, 3 case series, 3 retrospective studies, 2 prospective studies, 2 literature reviews. All studies concluded on the efficacy of olanzapine as an antiemetic in the palliative care setting. No serious adverse effects were reported. Based on the data from the literature review, we propose a therapeutic scheme adapted to the palliative care context. Conclusion Action of olanzapine on many receptors and its tolerance profile make it an interesting antiemetic treatment in palliative medicine. But to date, studies are scarce and have a low statistical power. Further investigation is therefore needed to determine the benefit of this treatment in palliative care patients, compared to usual treatments.

show abstract

Section: Galenic Formsmentioning

confidence: 99%